KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $7.5 billion.

  • Charles River Laboratories International's Liabilities and Shareholders Equity fell 612.24% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 billion, marking a year-over-year decrease of 654.75%. This contributed to the annual value of $7.5 billion for FY2024, which is 813.49% down from last year.
  • Charles River Laboratories International's Liabilities and Shareholders Equity amounted to $7.5 billion in Q3 2025, which was down 612.24% from $7.6 billion recorded in Q2 2025.
  • Charles River Laboratories International's Liabilities and Shareholders Equity's 5-year high stood at $8.2 billion during Q4 2023, with a 5-year trough of $5.8 billion in Q1 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $7.5 billion, with a median of $7.6 billion in 2025.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 3539.19% in 2021, then crashed by 813.49% in 2024.
  • Over the past 5 years, Charles River Laboratories International's Liabilities and Shareholders Equity (Quarter) stood at $7.0 billion in 2021, then rose by 8.24% to $7.6 billion in 2022, then rose by 7.79% to $8.2 billion in 2023, then decreased by 8.13% to $7.5 billion in 2024, then dropped by 0.19% to $7.5 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $7.5 billion for Q3 2025, versus $7.6 billion for Q2 2025 and $7.6 billion for Q1 2025.